Page 111 - NobleCon20-Book-Project

Lisata Therapeutics, Inc.

SELECTED FINANCIAL ITEMS LSTA

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (6.03) (6.60) (5.52) (5.34) (23.49)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (5.37) (5.40) (5.04) (4.93) (20.74)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 54.69 48.24 42.57 38.20 38.20
Cash & Short Term Investments 22.59 21.81 28.29 19.51 19.51
% of Assets 41% 45% 66% 51% 51%
Current Assets -Total 53.92 47.56 41.98 37.69 37.69
% of Assets 99% 99% 99% 99% 99%
Total Liabilities 6.80 5.50 4.58 4.76 4.76
% of Assets 12% 11% 11% 12% 12%
Current Liabilities - Total 6.59 5.33 4.46 4.69 4.69
% of Assets 12% 11% 10% 12% 12%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 47.89 42.74 38.00 33.44 33.44
% of Assets 88% 89% 89% 88% 88%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (4.07) (7.03) (5.28) (2.52) (18.90)
Net Cash Flow - Investing (5.71) 6.44 11.71 (6.31) 6.13
Net Cash Flow - Financing 0.02 (0.14) 0.03 0.00 (0.09)

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference